Skip to main content
IVBXF logo

Innovent Biologics, Inc. (IVBXF) Stock Price & Analysis

Innovent Biologics, Inc. (IVBXF) — price $10.93 (0.00%), as of the Nov 19, 2026 trading session; market cap $19.1B. Expected results Mar 31, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$10.93 $0.00 (0.00%) Market Cap $19.1B

Innovent Biologics, Inc. · IVBXF · Healthcare · Biotechnology

Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • ALNY · Alnylam Pharmaceuticals, Inc. · 72 /100
  • ASND · Ascendis Pharma A/S · 96 /100
  • NBIX · Neurocrine Biosciences, Inc. · 95 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$10.93
Change on the day0.00%
52-week range$9.10–$15.01
Market capitalisation$19.1B—
Price / earnings (trailing)99.12
Shares traded on the day900
Beta (volatility vs the S&P 500)0.24

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 10, 2025 to Nov 19, 2026: low $9.79, high $15, latest $11. 2 reported quarters marked, 1 above and 1 below the recorded estimate. $15 $9.79 high $15 Mar 26, 2026 · Earnings results · reported below the recorded estimate · close $111Aug 25, 2026 · Earnings results · reported above the recorded estimate · close $152 Oct 10, 2025 Nov 19, 2026 · $11 $12Oct 10, 2025$11Oct 24, 2025$11Nov 7, 2025$11Nov 21, 2025$12Dec 5, 2025$11Dec 19, 2025$11Jan 2, 2026$11Jan 16, 2026$10Jan 30, 2026$11Feb 13, 2026$11Feb 27, 2026$11Mar 13, 2026$11Mar 27, 2026$11Apr 10, 2026$10Apr 24, 2026$10May 8, 2026$10May 22, 2026$10Jun 5, 2026$9.96Jun 18, 2026$11Jul 2, 2026$12Jul 17, 2026$11Jul 31, 2026$12Aug 14, 2026$15Aug 28, 2026$12Sep 11, 2026$12Sep 25, 2026$12Oct 9, 2026$12Oct 23, 2026$11Nov 6, 2026$11Nov 19, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Innovent Biologics (IVBXF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Strong
Debt/Equity Moderate
ROE Neutral
Gross Margin Strong

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Innovent Biologics (IVBXF), and what does it report?

Short answer

Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. Innovent Biologics, Inc. (IVBXF) is classified as Healthcare / Biotechnology. SEC filing business address: 120 Broadway, 32ND Floor, NEW York, NY, 10271. It employs 7,502 people and is led by De-Chao Yu. In Q2 FY2026 it reported revenue of CN¥8.50B and net income of CN¥1.24B. The market values it at $19.1B.

2 · Latest results

What do the latest results show for Innovent Biologics (IVBXF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CN¥8.50B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.27B Aug 25, 2026
Latest report · revenue estimate
$1.31B Aug 25, 2026
Latest report · revenue vs estimate
Below estimate Aug 25, 2026
Latest report · EPS vs estimate
Above estimate Aug 25, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Aug 25, 2026$1.27B$1.31B$0.1030$0.0692
Mar 26, 2026$1.01B$985.90M−$0.0014$0.0172
Aug 27, 2025$830.16M$790.35M$0.0687$0.0251
Mar 26, 2025$749.12M$637.09M$0.0250−$0.0315
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CN¥8.50BCN¥1.24BCN¥0.68 (diluted)
Q4 FY2025CN¥6.97B-CN¥20M-CN¥0.02 (diluted)
Q2 FY2025CN¥5.95BCN¥834MCN¥0.49 (diluted)
Q4 FY2024CN¥5.47BCN¥298MCN¥0.18 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Innovent Biologics (IVBXF)?

Short answer · as of

The distress and quality screens read Altman Z 4.21 · Piotroski F 7. Trailing ratios: ROE 7.0% · ROA 2.2% · current ratio 2.68.

4 · What to check next?

What should you watch next at Innovent Biologics (IVBXF)?

Short answer · as of

The next earnings report is expected on Mar 31, 2027.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held IVBXF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported IVBXF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Innovent Biologics (IVBXF) — Healthcare

These answers are editorial: 1 of these 8 answers is drawn from the IVBXF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is IVBXF a good stock to buy?

Stock Expert AI does not rate IVBXF buy, sell or hold. Innovent Biologics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the IVBXF stock price today?

The last price recorded for Innovent Biologics, Inc. (IVBXF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for IVBXF?

Innovent Biologics, Inc. faces several key risks inherent to the biopharmaceutical industry and its market position. A primary risk is the high failure rate associated with clinical trials; any setbacks or failures in its extensive pipeline could lead to significant financial losses and delays in bringing new therapies to market.

What are the key factors to evaluate for IVBXF?

Evaluate IVBXF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. For example, collaborations can facilitate co-development of novel therapies or provide pathways for international commercialization, expanding Innovent's reach beyond China. Not financial advice.

How frequently does IVBXF data refresh on this page?

IVBXF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven IVBXF's recent stock price performance?

Innovent Biologics, Inc. (IVBXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive and diversified pipeline of antibody drug candidates across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider IVBXF overvalued or undervalued right now?

The trailing P/E of Innovent Biologics, Inc. (IVBXF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research IVBXF before investing?

Before investing in Innovent Biologics, Inc. (IVBXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 39 figures on this page — 1 from SEC filings and earnings calls, 32 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.